Credit Suisse Asset Management Income Fund, Inc.CIK

Credit Suisse Asset Management Income Fund, Inc. (CIK) is a closed-end management company whose income mandate is currently being administered by a set of advisers operating under a court-approved consent judgment that technically expired on 12 June 2024-so the fund’s ability to keep paying income to shareholders now depends on a board-approved bridge that may not have legal wheels left. The 21 June 2024 8-K confirms Ernst & Young’s engagement was green-lit by the board on the same day the judgment lapsed, creating a regulatory gap that looks less like careful risk management and more like a filing trail stack left ajar in a hurricane.

The fund itself is part of a larger UBS-managed platform whose UK ETF and fund pages display prices and product details under the anodyne heading ‘Below you will find funds details and prices for those funds available in your jurisdiction and for your investor type’-a phrase that reads less like investor confidence and more like the boilerplate on a parking-ticket appeal form. The fund’s income story is told through UBS-branded wrappers rather than through any filed revenue or dividend metrics, so the only concrete evidence we have is the board’s vote and the court’s expiry, not the portfolio’s cash-generating capacity.

The 13 December 2023 8-K shows Credit Suisse continued to provide advisory services despite the consent judgment, yet the court order’s expiry date remains the hard stop. The fund’s income mandate is therefore being run by a temporary crew with a deadline, which is fine for a film set but less reassuring for shareholders expecting reliable payouts. The board’s approval of Ernst & Young in June 2024 feels like re-booking the catering for the last day of shooting after the lead actor has already left the studio.

For context on the wider platform, UBS’s global media rail lists quarterly financial results and investor releases, but none of those pages supply CIK-specific revenue, net income, EPS, or cash-flow data. The fund’s own regulatory filings do not surface any of those figures either, so the income story is being told in regulatory language rather than in financial numbers. The ETF and fund pages on the UBS UK site show only wrapper-level prices and jurisdictions, not the underlying portfolio’s yield or liquidity metrics. (source: Latest media releases, https://www.ubs.com/global/en/media.html; UBS ETFs, https://www.ubs.com/uk/en/assetmanagement/funds/etf.html; Funds and prices, https://www.ubs.com/uk/en/assetmanagement/funds/asset-class.html)

The fund’s chart context is therefore thin: there is no CIK-specific price series or volume data in the evidence, and the wrapper-level pages do not expose underlying portfolio yields. If you need a visual, the fund’s public story is currently a set of static product pages with no live metrics, while its regulatory narrative is a loop of board votes and court dates. The only moving parts are the dates on the filings, and they are moving toward an expiry. (source: UBS product/news rail, https://www.ubs.com/uk/en/assetmanagement/funds/asset-class.html)

The fund’s story is therefore one of legal continuity rather than financial performance: the board keeps approving advisers, the court’s grace period keeps expiring, and the income mandate keeps running on fumes. Until a fresh 8-K or annual report supplies revenue, net income, EPS, or cash-flow figures, the fund’s true income-generating capacity remains an unproven claim rather than a filed fact. The gap between the polished platform story and the balance sheet is currently measured in regulatory grace days rather than dividend payouts.